Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone

Unidad de Enfermedades Infecciosas, Hospital Universitario de Valme, Sevilla, Spain.
Journal of Antimicrobial Chemotherapy (Impact Factor: 5.44). 10/2008; 62(6):1365-73. DOI: 10.1093/jac/dkn420
Source: PubMed

ABSTRACT To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a nucleos(t)ide reverse transcriptase inhibitor [N(t)RTI] backbone consisting of abacavir plus lamivudine with that observed in subjects who receive tenofovir plus lamivudine or emtricitabine.
A total of 256 subjects, enrolled in a cohort of 948 HIV-infected patients who received pegylated interferon and ribavirin from October 2001 to January 2006, were included in this study. All patients were taking one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor and abacavir plus lamivudine or tenofovir plus lamivudine or emtricitabine as N(t)RTI backbone during HCV therapy. Sustained virological response (SVR) rates in both backbone groups were compared.
In an intention-to-treat analysis, 20 out of 70 (29%) individuals under abacavir and 83 out of 186 (45%) under tenofovir showed SVR (P = 0.02). N(t)RTI backbone containing tenofovir was an independent predictor of SVR in the multivariate analysis [adjusted odds ratio (95% CI), 2.6 (1.05-6.9); P = 0.03]. The association between abacavir use and lower SVR was chiefly seen in patients with plasma HCV-RNA load higher than 600 000 IU/mL and genotype 1 or 4. Among patients treated with ribavirin dose <13.2 mg/kg/day, 3 (20%) of those under abacavir versus 22 (52%) under tenofovir reached SVR (P = 0.03), whereas the rates were 31% and 38% (P = 0.4), respectively, in those receiving >/=13.2 mg/kg/day.
HIV-infected patients who receive abacavir plus lamivudine respond worse to pegylated interferon plus ribavirin than those who are given tenofovir plus lamivudine or emtricitabine as N(t)RTI backbone, especially in those receiving lower ribavirin doses.

Download full-text


Available from: Antonio Rivero, Jul 02, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) infections are major public health problems. Patients at risk for HIV infection are likely also at risk for HCV and HBV because of shared routes of transmission. HIV and antiretroviral therapy (ART) have a significant impact on HCV and HBV. HIV coinfection accelerates HCV and HBV natural history, leading to an increased incidence of cirrhosis, development of hepatocellular carcinoma (HCC), and death. Universal screening for HCV and HBV infections in HIV-infected patients is essential. Proper screening combined with up-to-date treatment strategies can prevent these complications. This review focuses on important aspects and recent developments in the rapidly evolving field of coinfection.
    Current Hepatitis Reports 08/2009; 8(3):103-110. DOI:10.1007/s11901-009-0015-9
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Audit standards: 1. All new HIV-positive patients should be screened for HBV and HCV markers. 2. All HBV non-immune patients should be vaccinated. 3. All HIV-positive patients should have their HBV and HCV status measured before commencement of antiretroviral therapy. 4. All HBV-and HCV-infected patients should be vaccinated against hepatitis A if non-immune. 5. All HCV-positive patients non-immune to HBV should be vaccinated. 6. All HBV-and HCV-infected patients should have documented evidence in their case notes of a discussion on alcohol avoidance and how to reduce the risks of transmission. 7. Case notes of new HBV-positive patients should contain evidence of an attempt to contact household and sexual contacts and offer vaccination if non-immune. 8. Case notes of new HCV-positive patients should contain evidence of an attempt to notify parenteral and sexual contacts and offer them a test. 9. All patients who are HBsAg-positive or HCV-positive should have a clear antiviral treatment plan written in their notes at least once a year. 10. All HCV-RNA-positive patients should have an HCV viral load and genotype performed. 11. All HBV-positive patients should have their 'e' status checked, an HBV DNA viral load and an anti-HDV antibody test. 12. All patients with chronic HBV or HCV should be offered an assessment of liver fibrosis by either liver biopsy, hepatic elastography or other validated non-invasive fibrosis test unless they have a specified contra-indication. 13. All HBV-positive patients with an HBV DNA >2000IU/mL and evidence of liver damage should be offered treatment. 14. All HCV-RNA-positive patients should be offered treatment unless there is a specific contra-indication. 15. All patients with cirrhosis should be jointly treated by a hepatologist and have regular assessments for hepatocellular carcinoma according to risk.
  • Value in Health 11/2006; 9(6). DOI:10.1016/S1098-3015(10)63251-2 · 2.89 Impact Factor